April 2018
Select insulins with comparable alternatives won’t be covered, effective June 1, 2018
To address the high cost of drugs and provide the best value for our members, Blue Cross Blue Shield of Michigan and Blue Care Network commercial plans won’t be covering all formulations of the following insulin products for all drug lists, effective June 1, 2018:
- Apidra®, Apidra® Solostar®
- Humalog® (except Junior Kwikpen®), Humalog® Mix
- Humulin® (except U-500), Humulin® Kwikpen®
- Insulin products of the same type are interchangeable and work the same way to lower A1c. The following table includes covered comparable alternatives available at a lower cost to the member:
Insulin products not covered beginning June 1, 2018 |
Cost to Blue Cross (PPO) member |
Cost to Blue Care Network (HMO) member |
Apidra®, Apidra® Solostar |
Full cost (not covered) |
Full cost (not covered) |
Humalog® (except Junior Kwikpen®), Humalog® Mix |
Humulin® (except U-500), Humulin® Mix |
Covered alternatives |
Cost to Blue Cross (PPO) member |
Cost to Blue Care Network (HMO) member |
Novolin® (all forms) |
Preferred brand copayment |
Generic copayment |
Novolog®, Novolog® Mix |
This was already effective Jan. 1, 2018, for the Custom Select Drug List.
As part of this ongoing initiative, Blue Cross and BCN will continue to identify select drugs and stop covering them when there are more cost-effective or over-the-counter alternatives available for our commercial members.
|